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Abstract 
Background 
While many risk factors for Atrial Fibrillation (AF) have been identified, there are important differences in 
their relative impact between sexes. The aim of our study was to investigate the influence of sex as a long-term 
predictor of adverse events in “real world” AF patients treated with direct oral anticoagulants. 
Methods 
The FANTASIIA registry is a prospective, national and multicentric study including outpatients with 
anticoagulated AF patients. Baseline characteristics and adverse events at 3 years of follow-up were collected 
and classified by sex. Cox multivariate analysis was performed to investigate the role of sex in major events 
and composite outcomes. 
Results 
A total of 1956 patients were included in the study. 43.9% of them were women, with a mean age of 
73.8 ± 9.4 years (women were older 76.5 ± 7.9 vs 71.7 ± 10.1, p<0.001). Women had higher rate of 
cardiovascular risk factors and higher mean of CHA2DS2-VASc (4.4 ± 1.4 vs 3.7 ± 1.6, p<0.001) and HAS-
BLED (2.1 ± 1.0 vs 1.9 ± 1.1, p<0.001) than men. After 3 years of follow-up, rates of major events were similar 
in both groups with limit difference for all-cause mortality (4.4%/year in women vs 5.6%/year in 
men; p = 0.056). However, all the composite events were more frequent in women. We observed in the non-
adjusted adverse events lower rate of all-cause mortality (HR 0.62, 95%CI 0.47–0.81; p<0.001), composite 1 
outcomes (HR 0.80, 95%CI 0.65–0.98; p = 0.029) and composite 2 (HR 0.77, 95%CI 0.64–0.94; p = 0.010) in 
women compared with men. In multivariate Cox regression analysis observed that female sex was an 
independently protector factor for all-cause mortality and for the composite outcomes 1 and 2. 
Conclusions 
In this “real world” study of anticoagulated AF patients, women could have a protective role against 
development of adverse events, mainly on all-cause mortality and combined events. 
Keywords 
Atrial fibrillation; Role of sex; Direct oral anticoagulants; Vitamin K antagonists; FANTASIIA registry 
 
AF         Atrial fibrillation 
INR       International normalized ratio 
LVEF    Left ventricular ejection fraction 
DOAC   Direct oral anticoagulants 
TTR       Time in therapeutic range 




Atrial fibrillation (AF) is the most frequently cardiac arrhythmia in developed countries [1] and 
several studies have been described that in both developed and developing countries, the age-
adjusted incidence and prevalence of AF are lower in women [1]. The detection of AF is associated 
with an important morbidity and mortality rate, with an increase in admissions and health 
costs [1], [2], [3], [4], [5], [6]. AF is a leading risk factor for stroke and related with one-third of all 
ischemic cerebrovascular events [3], [7]. Different clinical factors included in thromboembolic and 
bleeding scores are markers of prognosis in AF patients [1], [8]. Female sex has been considered a 
prognostic factor of AF embolic complications and therefore confers 1 point on CHA2DS2-VASc 
score [1], [2], [3]. However, the presence of female sex as risk factor has not been strongly 
confirmed in the literature and nowadays there are important doubts about the role of women per 
se as an independent factor of poor prognosis in AF [10], [11]. For that reason, the European Society 
of Cardiology (ESC) AF guidelines [1] do not recommend oral anticoagulant treatment in patients 
with AF and a CHA2DS2-VASc score of 1 when the only factor present is female sex itself. 
 
It is well known that women presented AF at least a decade later than men and paroxysmal AF 
form the most common presentation in addition to the presence of dyspnea, fatigue or 
palpitations [12], [13]. Although women received similar anticoagulant therapies than men, 
electrical cardioversion or ablation procedures are less frequent in women [14], [15], [16], [17]. 
However, the analysis of direct effect of sex as long-term predictor of adverse events in “real world” 
AF patients under oral anticoagulation therapy in the literature is scarce and not homogeneous in the 
conclusions [18]. 
 
The objective of this study was to investigate the role of sex as a long-term predictor of adverse 




The data from this study come from the FANTASIIA Registry (Spanish acronym of “Fibrilación 
Auricular: influencia del Nivel y Tipo de Anticoagulación Sobre la incidencia de Ictus y Accidentes 
hemorrágicos”), a national, multicentric, observational and prospective study that collects general 
information about the baseline characteristics and situation of AF population (paroxysmal, 
permanent or persistent AF) in Spain. The main objective of The FANTASIIA registry was to 
evaluate the incidence of thromboembolic and hemorrhagic events in a prospective sample of 
patients with AF over 3 years of follow-up, in relation to the type of antithrombotic agents used, 
VKA or DOAC, and the quality of anticoagulation (in those who receive VKA). The design of 
FANTASIIA registry was previously published [14], [19]. In brief, this registry includes an initial 
visit and three follow-up visits, after one, two and three years. Clinical and analytical data of patients 
were collected in an electronic data notebook. In this substudy, we focused on the role of sex as a 
long-term predictor of adverse events in this population. 
Study population 
A total of 1956 consecutive outpatients treated with VKA or DOAC were included in the analysis 
of the present study. All patients were followed in an outpatient clinics by 81 researchers, 81% of 
them were cardiologists, 11% were primary care physicians and 8% were internists, from June 2013 
to December 2014. Above 50 centers throughout Spain were involved, stratified by levels of 
assistance and randomly selected. According to the FANTASIIA registry design, all patients 
received anticoagulant treatment, per protocol 25% with DOAC and 75% with VKA, at least during 
six months prior to inclusion. AF patients were older than 18 years old and clinical management was 
carried out according current clinical practice. Demographic, clinical and analytical variables were 
collected from all patients in medical records. Symptoms related with AF presence were evaluated 
following the European Heart Rhythm Association (EHRA). Patients were classified as follows: 
EHRA I: ‘No symptomsʼ; EHRA II: ‘Mild symptoms’, normal daily activity not affected; EHRA 
III: ‘Severe symptoms’, normal daily activity affected; EHRA IV: ‘Disabling symptoms’, normal 
daily activity discontinued. Patients with rheumatic mitral valvular disease or prosthetic valve 
patients were excluded [20]. 
 
The FANTASIIA Registry complies with all the requirements of the Helsinki Declaration and 
the study protocol was approved by the Clinical and Ethical Testing Committee of the Hospital 
Universitario San Juan de Alicante (approval number 12/220) by all Ethics Committees of the 
participating centers, as well as the Spanish Agency for Medicine and Health Products (SEC-ACO-
2012-01 post-authorization approval code). All the participating patients signed the informed 
consent. 
 
For the present analysis, we included all patients that have been completed three years of follow 
up. 
Role of sex as predictor of prognosis 
We compared two groups of patients divided by sex, women versus men. Baseline 
characteristics, risk factors, comorbidities such as history of heart disease, previous stroke or renal 
dysfunction were collected. Time in therapeutic range (TTR) was assessed by Rosendaal method. 
We also collected all adverse events (stroke, embolic events, major bleeding, major adverse 
cardiovascular events (MACE), all-cause and cardiovascular mortality rates) after 3 years of follow-
up. Thromboembolic events were defined as ischaemic stroke or transient ischaemic attack and 
peripheral artery embolism. Strokes were defined as ischaemic stroke, transitory ischaemic attack 
and haemorrhagic stroke. All strokes were evaluated by computed tomographic (CT) scan or 
magnetic resonance imaging (MRI) according to the neurologist criteria. Major bleeding events were 
assessed according to the 2005 International Society of Thrombosis and Haemostasis 
criteria [21] fatal bleeding or symptomatic bleeding in a critical anatomical site (intracranial, 
intraspinal, intraocular, retroperitoneal, intraarticular, pericardial or intramuscular with 
compartment syndrome) and/or bleeding causing a fall in Hb≥2 g/dL, or transfusion of ≥2 units of 
packed red blood cells. We also recorded all-cause mortality and cardiovascular mortality, with the 
latter defined if it was secondary to a cardiovascular event (acute coronary syndrome, heart failure, 
lethal arrhythmia or sudden death, artery aneurysm rupture or stroke). Major adverse cardiovascular 
event (MACE) was defined as the composite of ischaemic stroke, myocardial infarction and 
cardiovascular mortality. We also performed composite events to assess the differences between 
sexes. Composite outcomes 1 included stroke, embolism, major bleeding or all-cause mortality. 
Composite outcomes 2 included stroke, embolism, major bleeding, all-cause mortality or myocardial 
infarction. Composite outcomes 3 included stroke, embolism, major bleeding or cardiovascular 
mortality. 
 
To guarantee the quality of the FANTASIIA registry, an external event assignment committee 
was formed to evaluate all adverse events. Cox multivariate analysis after adjusting for baseline 
confounding factors was performed to investigate the role of sex in predicting major adverse events. 
  
Statistical analysis 
Quantitative variables are described by mean and standard deviation or median and interquartile 
range based on whether they followed a normal distribution. To test the normal distribution, the 
Kolmogorov–Smirnov test was used. For comparisons among groups, T-student test was used in the 
case of continuous variables and Chi-square in the case of qualitative variables, considering the 
value of p <0.05 as statistically significant. Cox regression analyses were used to determine the 
associations between women sex and adverse outcomes. The independent effect of clinical variables 
on adverse clinical outcomes was calculated using a Cox proportional hazards regression, 
considering the clinical variables age, female sex, hypertension, diabetes mellitus, COPD, previous 
bleeding, previous stroke, CKD, heart disease, Charlson Index and antiarrhythmic drugs. After that, 
we included in the multivariate model only those values with p < 0.15 on univariate analysis. The 
results are presented as hazard ratio (HR) with a 95% confidence interval. STATA statistical version 
12.0 was employed for the statistical analysis. 
Results 
Comparison of baseline characteristics of both groups 
Of 1956 patients analyzed, 860 (43.9%) were women. The mean age was 73.8 ± 9.4 years, 
women older than men (76.5 ± 7.9 vs 71.7 ± 10.1, p<0.001). Table 1 shows the baseline 
characteristics of the population. Regarding to oral anticoagulation therapy in women, 219 (25.5%) 
received DOAC and 641 (74.5%) VKA (without differences by sex; p = 0.240). Regarding the 
quality of oral anticoagulation under VKA therapy, 52.4% of the whole sample had poor quality 
assessed by Rosendaal method (TTR<65%), without differences by sex (53.3% in women vs 
51.8%; p = 0.548). We also assessed cardiovascular risk factors and we only observed significant 
differences for hypertension (more frequent in women than men [84.3% vs 77.3%, p<0.001]), 
COPD apnea (less frequent in women than men [10% vs 23.4%, p<0.001]), mean CHA2DS2-VASc 
and HAS-BLED (both higher in women than men [4.35±1.37 vs 3.67±1.64, p<0.001] and 
[2.13±0.95 vs 1.91±1.11, p<0.001], respectively). Paroxysmal AF was more frequent in women than 
men (33.0% vs 26.1%, p = 0.004) but, regarding the management of AF, previous electrical 
cardioversion (14.1% vs 21.3%, p<0.001) and radiofrequency ablation (3.3% vs 5.1%, p = 0.045) 
were less frequent in women than men. The left ventricular ejection fraction was higher in women 
(60.9 ± 9.1% vs 56.7 ± 12.5%, p <0.001) than in men. Related with that finding, women showed 
less previous heart disease such as heart failure (25.2% vs 31.8%, p<0.001) and coronary heart 






Table 1. Baseline characteristics 
 Total  
1956 
Women 
n = 860 (43.9%) 
Men 
n = 1096 (56.1%) 
p-value 
Age (years) 73.8 ± 9.4 76.4 ± 7.8 71.7 ± 10.11 <0.001 
Hypertension 1574 (80.5) 725 (84.3) 847 (77.3) <0.001 
Dyslipidaemia 1021 (52.2) 446 (51.9) 573 (52.3) 0.860 
Diabetes 571 (29.2) 245 (28.6) 331 (30.2) 0.340 
COPD/sleep apnea 338 (17.3) 88 (10.0) 256 (23.4) <0.001 
Renal failure 378 (19.3) 168 (19.5) 209 (19.1) 0.790 
Previous stroke 334 (17.1) 136 (15.9) 195 (17.8) 0.276 
Thyroid dysfunction 219 (11.2) 150 (17.5) 67 (6.1) <0.001 
Drugs/alcohol abuse 74 (3.8) 6 (0.7) 67 (6.1) <0.001 
Major bleeding 80 (4.1) 33 (3.8) 47 (4.3) 0.617 
Charlson index 1.14±1.15 0.95±1.05 1.29±1.21 <0.001 
EHRA functional class 767 (39.2) 284 (33.0) 483 (44.1)  
(1-functional class I)     
2-functional class II 1025 (52.4) 475 (55.2) 554 (50.1) <0.001 
3- functional class III 156 (8.0) 95 (11.1) 63 (5.7)  
4-functional class IV 8 (0.4) 6 (0.7) 2 (0.2)  
Previous heart disease 941 (48.1) 359 (41.8) 578 (52.7) <0.001 
CHD 354 (18.1) 93 (10.8) 263 (24.0) <0.001 
Heart failure 569 (29.1) 217 (25.2) 349 (31.8) 0.001 
Coronary stents 180 (9.2) 44 (5.2) 139 (12.7) <0.001 
LVEF<40% 229 (11.7) 42 (4.9) 185 (16.9) <0.001 
Paroxysmal AF 569 (29.1) 284 (33.0) 286 (26.1) 0.004 
Permanent AF 966 (49.4) 405 (47.1) 560 (51.1) 0.004 
Rhythm control 773 (39.5) 332 (38.7) 413 (37.7) 0.660 
Ablation for AF 84 (4.3) 30 (3.3) 56 (5.1) 0.045 
LVEF 58.6 ± 11.4 60.9 ± 9.09 56.7 ± 12.5 <0.001 
CHA2DS2-Vasc 3.72±1.59 4.35±1.37 3.67±1.64 <0.001 
HAS-BLED 2.01±1.05 2.13±0.95 1.91±1.11 <0.001 
VKA 1483 (75.8) 641 (74.5) 842 (76.8) 0.240 
DOAC 473 (24.2) 219 (25.5) 254 (23.2)  
Diuretics 1123 (57.4) 549 (63.9) 572 (52.2) <0.001 
ACE inhibitors 602 (30.8) 208 (24.2) 392 (35.8) <0.001 
ARA 796 (40.7) 385 (44.8) 410 (37.4) 0.001 
MRA 272 (13.9) 99 (11.6) 172 (15.7) 0.008 
Statins 1078 (55.1) 448 (52.1) 628 (57.3) 0.022 
Antiplatelets 205 (10.5) 53 (6.2) 152 (13.9) <0.001 
Digoxin 354 (18.1) 173 (20.1) 183 (16.7) 0.060 
Antiarrhythmic 481 (24.6) 229 (26.6) 256 (23.4) 0.160 
CCB 472 (24.1) 224 (26.1) 246 (22.4) 0.160 
Beta-blockers 1179 (60.3) 523 (60.8) 657 (59.9) 0.690 
TTR (Rosendaal) 61.3 ± 25.1 60.8 ± 24.8 61.8 ± 25.2 0.357 
TTR < 65% 1025 (52.4) 458 (53.3) 568 (51.8) 0.548 
TTR<70% 1156 (59.1) 517 (60.1) 639 (58.3) 0.497 
AF: Atrial Fibrillation. COPD: Chronic obstructive pulmonary disease. EHRA: European Heart Rhythm Association. 
CHD: Coronary Heart Disease, LVEF: Left ventricular ejection fraction. ACE inhibitors: Angiotensin-converting-enzyme 
inhibitors, ARA: Aldosterone-receptor antagonists, MRA: Mineralocorticoid receptor antagonists. CCB Calcium channel 
blockers. VKA: Vitamin K Antagonists. DOAC: Direct oral anticoagulants. TTR: Time in Therapeutic Range. 
Adverse events during the follow-up 
After 3 years of follow-up, 5005.45 patients/year of observations were accumulated. Annual 
incidence of major events (women versus men, patients/year) for stroke, total embolisms, major 
bleedings, MACE, cardiovascular death and myocardial infarction were similar in both groups of 
patients, and with limit difference for all-cause mortality (4.4%/year in women vs 5.6%/year in 
men; p = 0.056). However, the composite events were more frequent in women. Table 2 reflected 
the distribution of adverse events according to sex and we observed significantly lower rate of the 
composite 1 outcomes (stroke, embolism, major bleeding or all-cause mortality) in women than men 
(6.8%/year vs 8.4%/year; p = 0.027) as well as lower rate of the composite 2 outcomes (stroke, 
embolism, major bleeding, all-cause mortality or myocardial infarction) in women than men 
(7.3%/year vs 9.3%/year; p = 0.009). We observed in the non-adjusted adverse events lower rate of 
all-cause mortality (HR 0.62, 95%CI 0.47–0.81; p<0.001), composite 1 outcomes (HR 0.80, 95%CI 
0.65–0.98; p = 0.029) and composite 2 (HR 0.77, 95%CI 0.64–0.94; p = 0.010) in women compared 
with men. 
 
We also performed a univariate (Supplementary Tables 1 and 2) and multivariate Cox regression 
analysis (Table 3) and observed that female sex was an independently protector factor for all-cause 
mortality and for the composite outcomes 1 and 2. 
Table 2. Distribution of adverse events according to sex after 3 years of follow-up. 
 
 Overall 
(n = 1956) 
Women 
(n = 860) 
Men 
(n = 1096) 
p-value 
Stroke 45 17 28  
0.397 
  Annual rate (%/year) 0.9%/year 0.8%/year 1.0%/year    0.397 
Major bleeding 146 63 83  
0.836 
  Annual rate (%/year) 2.9%/year 2.8%/year 3.0%/year    0.836 
Total embolisms 48 17 31  
0.227 
  Annual rate (%/year) 0.9%/year 0.8%/year 1.1%/year    0.227 
All-cause mortality 255 98 157  
0.056 
  Annual rate (%/year) 5.1%/year 4.4%/year 5.6%/year    0.056 
Cardiovascular mortality 107 51 56  
  Annual rate (%/year) 2.1%/year 2.3%/year 2.0%/year    0.428 
MACE 168 70 98  
  Annual rate (%/year) 3.4%/year 3.2%/year 3.5%/year    0.530 
Acute myocardial infarction 53 19 34  
  Annual rate (%/year) 1.2%/year 0.9%/year 1.3%/year    0.227 
Composite outcomes 1 385 150 235  
  Annual rate (%/year) 7.7%/year 6.8%/year 8.4%/year    0.227 
Composite outcomes 2 420 161 259  
  Annual rate (%/year) 8.4%/year 7.3%/year 9.3%/year    0.009 
Composite outcomes 3 266 114 152  
  Annual rate (%/year) 5.3%/year 5.1%/year 5.5%/year    0.695 
 
Stroke included ischaemic stroke, haemorrhagic stroke and transitory ischaemic attack. Thromboembolic events were defined 
as ischaemic stroke or transient ischaemic attack and peripheral artery embolism. MACE included the composite of ischaemic 
stroke, myocardial infarction and cardiovascular mortality. Composite outcomes 1: included stroke, embolism, major 
bleeding or allcause mortality. Composite outcomes 2: included stroke, embolism, major bleeding, all-cause mortality or 
myocardial infarction. Composite outcomes 3: included stroke, embolism, major bleeding or cardiovascular mortality. 
Table 3. Independent predictors of adverse clinical events by multivariate Cox regression analysis. 
 
 HR 95% CI p-value 
Thromboembolic events 
Previous stroke 2.13 1.16–3.91 0.014 
Major bleeding 
CKD 1.76 1.23–2.53 0.002 
Previous bleeding 2.76 1.58–4.82 <0.001 
Mortality 
Sex (female) 0.62 0.47–0.81 <0.001 
Age 1.08 1.06–1.10 <0.001 
COPD/sleep apnea 1.44 1.07–1.94 0.016 
CKD 1.47 1.13–1.93 0.005 
Previous bleeding 2.15 1.37–3.39 0.001 
Cardiovascular mortality 
Age 1.08 1.05–1.11 <0.001 
Heart failure 1.68 1.06–2.65 0.028 
Composite outcomes 1 
Sex (female) 0.64 0.52–0.80 <0.001 
Age 1.05 1.04–1.06 <0.001 
CKD 1.38 1.10–1.73 0.006 
Charlson index 1.19 1.09–1.30 <0.001 
Previous bleeding 2.02 1.35–2.95 <0.001 
Composite outcomes 2 
Sex (female) 0.65 0.52–0.80 <0.001 
Age 1.05 1.04–1.06 <0.001 
CKD 1.30 1.05–1.62 0.019 
Charlson index 1.18 1.08–1.28 <0.001 
Previous bleeding 1.94 1.33–2.83 0.001 
Composite outcomes 3 
Sex (female) 0.76 0.59–0.99 0.039 
Age 1.03 1.02–1.05 <0.001 
CKD 1.40 1.06–1.84 0.016 
Charlson Index 1.21 1.10–1.34 <0.001 
Previous major bleeding 1.75 1.07–2.88 0.027 
 
CKD: Chronic Kidney disease. COPD: Chronic obstructive pulmonary disease. HR: Hazard ratio.  
CI: Confidence interval. (For detailed multivariate analysis adjusted by different variables see supplementary tables.) 
 
Discussion 
The principal results of this ancillary study from the FANTASIIA Registry showed that female 
sex was associated with a less development of major cardiovascular events at long-term follow up, 
mainly in total death and combined events including embolisms and bleedings. 
 
The main result of our study indicates that women showed better long term prognosis with lower 
rates of all-cause mortality, and composite events besides they were older and with higher incidence 
of hypertension and higher CHA2DS2-VASc and HAS-BLED scores than men, like previous 
studies [22], [23], [24]. Probably, one of the main causes is related with less rate of previous heart 
disease in women and other is related with better oral anticoagulation therapy than men [12], [18]. 
In the same line, Pastori et al. [25] observed higher rate of adverse events in men with AF than in 
women and male sex was independent predictor of cardiovascular events. 
 
In previous studies female sex has been described as a risk factor for cardiovascular disease and 
death. Emdin et al. [9] in a systematic review and meta-analysis of cohort studies showed that AF 
was associated with a higher relative risk of all-cause mortality, stroke, cardiovascular mortality, 
cardiac events, and heart failure in women compared with men. On the other side, Nielsen et 
al. [11] performed a big study with 239,671 patients with AF with similar baseline characteristics as 
our registry (such as women with higher CHA2DS2-VASc score and older and they observed higher 
rates of stroke in women. Or that reason, the authors concluded that female sex is a risk modifier of 
stroke but with excess of risk in those with more than 2 non-sex related risk factors. 
 
Several reasons can explain the discrepancies between our results and those of Emdin et 
al. [9] First, the meta-analysis effect where previous studies have presented conflicting evidence of 
the effect of AF on the risk of death and cardiovascular disease in women: the ratio of relative risk 
was greater than one but not significant for 11 of the 19 studies (for death) and for 6 six of the 13 
studies (for stroke). Besides, in meta-analysis of observational studies, sex differences in the 
association of AF with risk of death and cardiovascular disease might be caused by unobserved 
confounding between sexes [17], [26]. Second, publication bias, because studies that detect an 
interaction between AF and risk of death and cardiovascular disease by sex might be more likely to 
be published. Third, differences in treatment, mainly anticoagulation, between the different 
observational studies with underuse of anticoagulants in women reported in many of the studies 
included [28]. Sex-specific differences in anticoagulant use have been observed in relation to OAC 
prescription (women were more likely to be prescribed antiplatelet agents rather than OAC), the 
chosen OAC agent (women were more likely to receive a DOAC when compared to warfarin), and 
OAC dosing (women require a lower mean warfarin dose [approximately 4.5 mg less per week when 
compared to men; p < 0.001], and women are more likely to be prescribed the lower approved 
DOAC dose) [1], [2], [3], [4], [5]. In this sense, our study population was fully anticoagulated 
without any difference by sex in quality and type of oral anticoagulation therapy [29]. 
 
Moreover, in the current analysis, we observed differences in presentation and clinical symptoms 
of AF between sexes; women presented more frequently symptomatic paroxysmal AF and were 
more symptomatic compared with men with a functional ERHA class II, III and IV significantly 
more frequent in women (p<0.001) than men. These facts were in accordance to previous studies 
such as ORBIT-AF registry [30], EORP-AF pilot survey [15], and PREFER AF registry [22]. In our 
study, as in those others before [15], [22], rhythm control strategy was less frequent in women 
despite a higher rate of symptomatic AF. Indeed, electrical cardioversion and radiofrequency 
ablation were less frequent in women. In this way, a meta-analysis of all AF ablation clinical trials 
reported that women constitute only one-fifth of the study population [31]. However, in this analysis, 
all explorations, diagnosis and initial treatments data were similar in both groups. Thus, the use of 
anticoagulants was also similar in both, women and men. 
 
 
Finally, after multivariate adjustment, we observed lower rates of adverse events in women, 
specially in the rate of stroke although female sex is a risk factor in CHA2DS2-VASc score. The 
results of this study due to their limited statistical power should be analyzed with caution; however, 
our results were in accordance to the current literature. In accordance, the study of Renoux et 
al. [32] from the Quebec cohort did not support female sex as an independent risk factor for stroke 
and they found that mortality rates were lower in women compared with men at any age, whereas 
the risk of bleeding was also slightly lower in women. However, Andrade et al. [27] observed that 
risk was elevated for both sexes, but the relative increase in mortality has been suggested to be 
higher for women. Although the results of individual studies can be contradictory, a large meta-
analysis demonstrated that the pooled ratio of relative risks for of all-cause mortality was 12% 
greater in women versus men (RR 1.12, 95%CI 1.07–1.17). This meta-analysis also showed the poor 
oral anticoagulation management in women unlike our results. 
Study limitations 
The principal limitation of this “real world” analysis, come from its design as an observational 
study. Indeed, the les rate of structural heart disease in women could be unobserved confounding 
factor. Although the prospective design of the study, acceptable duration of the follow up and correct 
statistical analysis made improbable the presence of confounding factors, any bias due the sample 
size could have influenced the principal results 
Conclusions 
In this substudy from the real world FANTASIIA prospective registry, female sex seems to play 
a protective role against the development of major cardiovascular events, mainly on total death and 
combined events including embolisms and bleedings in AF patients. These data suggest that, after 
control the influence of poor oral anticoagulation therapy, female sex is not a risk factor of worse 
prognosis in AF patients. 
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